Novartis AG (NVS)

87.40
1.20 1.30
NYSE : Health Technology
Prev Close 86.24
Open 87.30
Day Low/High 87.22 / 87.57
52 Wk Low/High 72.30 / 94.19
Volume 1.70M
Avg Volume 1.81M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 216.58B
EPS 3.30
P/E Ratio 26.00
Div & Yield 2.49 (2.90%)

Latest News

A Reckless Fed: Market Recon

A Reckless Fed: Market Recon

It's time for the central bank to show the same level of concern for their misplaced aggression.

Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.

Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.

Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark

Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark

The rating is based on an analysts' view that Wednesday's full legalization of cannabis in Canada will be a boon for the company.

Novartis Analysis Shows Crizanlizumab (SEG101) Increased The Number Of Patients Free Of Sickle Cell Pain Crises Vs Placebo During SUSTAIN Study

Novartis Analysis Shows Crizanlizumab (SEG101) Increased The Number Of Patients Free Of Sickle Cell Pain Crises Vs Placebo During SUSTAIN Study

- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.

Novartis Is Ready to Rally From a Large Base Pattern

Novartis Is Ready to Rally From a Large Base Pattern

Let's check out the latest charts and indicators for some technical guidance.

Jim Cramer: Reefer Madness

Jim Cramer: Reefer Madness

Tilray's a disruptive company for many industries.

Teva Shares Pop as FDA Approves Its Migraine Drug

Teva Shares Pop as FDA Approves Its Migraine Drug

Ajovy is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the FDA to prevent migraines.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Biotech Stocks Getting Their Due Respect

Biotech Stocks Getting Their Due Respect

Here are two I think will bounce back before the end of the year.

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.

Three Key Takeaways From Healthcare Earnings Season

Three Key Takeaways From Healthcare Earnings Season

Drug pricing remains front and center as healthcare companies start reporting quarterly results.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

Comcast Is Among 8 Stocks That Are Ready to Change Direction

Comcast Is Among 8 Stocks That Are Ready to Change Direction

These names are showing bullish or bearish reversal patterns over the past week.

Novartis Launches The Galaxies Of Hope App, A Digital Experience For The Neuroendocrine Tumor (NET) Cancer Community

Novartis Launches The Galaxies Of Hope App, A Digital Experience For The Neuroendocrine Tumor (NET) Cancer Community

- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices of patients, caregivers, and physicians in the NET...

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.

Stocks Stumble at Friday's Close, Giving Up Most of Day's Gains

Stocks Stumble at Friday's Close, Giving Up Most of Day's Gains

Stocks ended slightly higher Friday, after giving up most of the day's gains in the final minutes of trading.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed the last day of June trading on a high note Friday.

Novartis Doesn't Appear Ready to Make Healthy Move Higher

Novartis Doesn't Appear Ready to Make Healthy Move Higher

The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.

Nike, Deutsche Bank, Goldman Sachs and Novartis - 5 Things You Must Know

Nike, Deutsche Bank, Goldman Sachs and Novartis - 5 Things You Must Know

U.S. stock futures are rising Friday and global stocks rebound on strong gains in China; Deutsche Bank is higher even after receiving a fresh rebuke from the Fed over 'critical deficiencies' in its financial planning; Nike's sales in North America bounce back.

Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning

Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning

Happy Friday! These are the stories you must know ahead of the opening bell.

Novartis Survey Uncovers Real-world Impact Of Immune Thrombocytopenia Or ITP, A Rare Blood Disease, On Patients' Quality Of Life

Novartis Survey Uncovers Real-world Impact Of Immune Thrombocytopenia Or ITP, A Rare Blood Disease, On Patients' Quality Of Life

-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

TheStreet Quant Rating: A- (Buy)